[BOOK][B] Bibliography of research on ocean fronts, 1964-1984
LB Gilham, JJ Mika, DA Wiesenburg - 1985 - apps.dtic.mil
This report contains a bibliography of published papers describing research related to oceanic
fronts. The citations cover research on physical, chemical and biological ocenographic …
fronts. The citations cover research on physical, chemical and biological ocenographic …
Tuberculosis screening before biologics—T-SPOT for all?
L Gilham, J France, A Stirling, S Bawa - The Journal of Rheumatology, 2011 - jrheum.org
There remains considerable uncertainty and widespread variation in practice throughout
rheumatology departments in the UK of screening methods for latent tuberculosis (LTB) prior to …
rheumatology departments in the UK of screening methods for latent tuberculosis (LTB) prior to …
[PDF][PDF] NORDA Technical Note 303
LB Gilham, JJ Mika, DA Wiesenburg - 1985 - apps.dtic.mil
This report contains a bibliography of published papers describing research related to oceanic
fronts. The citations cover research on physical, chemical and biological oceanographic …
fronts. The citations cover research on physical, chemical and biological oceanographic …
[HTML][HTML] Apabetalone downregulates factors and pathways associated with vascular calcification
D Gilham, LM Tsujikawa, CD Sarsons, C Halliday… - Atherosclerosis, 2019 - Elsevier
Background and aims Apabetalone is an inhibitor of bromodomain and extraterminal (BET)
proteins. In clinical trials, apabetalone reduced the incidence of major adverse cardiac …
proteins. In clinical trials, apabetalone reduced the incidence of major adverse cardiac …
[HTML][HTML] RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular …
D Gilham, S Wasiak, LM Tsujikawa, C Halliday… - Atherosclerosis, 2016 - Elsevier
High density lipoproteins (HDL), through activity of the main protein component apolipoprotein
AI (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess …
AI (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess …
[HTML][HTML] Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208)
S Wasiak, D Gilham, LM Tsujikawa, C Halliday… - Journal of …, 2017 - Springer
Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease
(CVD) that targets BET proteins. Through transcriptional regulation RVX-208 modulates …
(CVD) that targets BET proteins. Through transcriptional regulation RVX-208 modulates …
Clinical progression of cats with early‐stage chronic kidney disease fed diets with varying protein and phosphorus contents and calcium to phosphorus ratios
…, JC Coltherd, J Atwal, M Gilham… - Journal of Veterinary …, 2021 - Wiley Online Library
Background Dietary protein and phosphorus (P) restriction is the mainstay for nutritional
management of chronic kidney disease (CKD). However, adequate restriction levels for cats …
management of chronic kidney disease (CKD). However, adequate restriction levels for cats …
[HTML][HTML] Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
D Gilham, S Wasiak, BD Rakai, L Fu, LM Tsujikawa… - Biomedicines, 2023 - mdpi.com
Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney
disease (CKD). Apabetalone is an orally available inhibitor of bromodomain and extraterminal (…
disease (CKD). Apabetalone is an orally available inhibitor of bromodomain and extraterminal (…
Clinical Grade manufacture of CYAD-101, a NKG2D-based, First in Class, non–gene-edited allogeneic CAR T-Cell therapy
…, E Gauthy, S Agaugué, DE Gilham… - Journal of …, 2022 - journals.lww.com
Allogeneic chimeric antigen receptor (CAR) T holds the promise of taking this therapeutic
approach to broader patient populations while avoiding the intensive manufacturing demands …
approach to broader patient populations while avoiding the intensive manufacturing demands …
[HTML][HTML] Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
CD Sarsons, D Gilham, LM Tsujikawa, S Wasiak, L Fu… - Biomedicines, 2023 - mdpi.com
Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate
expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream …
expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream …